John R. Guyton, MD
- Medicine / Medicine-Endocrinology and Metabolism
- Pathology
Address
DUMC 3510
Durham, NC 27710
Appointment Telephone
919-620-5300
Office Telephone
919-684-9036
Fax Telephone
919-681-7796
- MD, Harvard Medical School (Massachusetts), 1973
- Medicine, University of Texas Southwestern Hospitals, 1973-1976
- Pathology, Diabetes Research, Endocrinology, Harvard Medical School (Massachusetts), 1976-1979
Clinical Interests
Lipid disorders (cholesterol and triglyceride), metabolic syndrome, coronary prevention, atherosclerosis regression
Research Interests
Current research efforts focus on the role of niacin in clinical lipid practice. Despite the ending of a large clinical trial due to lack of benefit, niacin remains the second best lipid-modifying drug after statins. Why this trial did not replicate earlier success with niacin is a matter of great interest. Counterregulatory hormone responses may provide the answer. Another research focus is weight loss counseling in the busy clinic setting. Low glycemic dietary advice achieved average long-term weight loss of 3% (beyond 1 year) in a recently published study. One in four patients had long-term weight loss greater than 6%.
Dr. Guyton is recognized nationally as an expert in clinical management of lipid disorders and a leader in postgraduate education in this area. Both nationally and internationally, Dr. Guyton is known for his earlier work on lipid deposition in the arterial wall.
Key words: atherosclerosis, lipoproteins, statins, niacin, triglycerides, low density lipoproteins, high density lipoproteins
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Amarin
- Amgen, Inc.
- Eli Lilly & Co.
- GlaxoSmithKline
- Isis Pharmaceuticals, Inc.
- Merck & Co. USA (not assoc'd with Merck KGaA)
- Regeneron Pharmaceuticals
- Sanofi-Aventis
Representative Publications
Bailey, WA; Westman, EC; Marquart, ML; Guyton, JR. Low glycemic diet for weight loss in hypertriglyceridemic patients attending a lipid clinic. Journal of Clinical Lipidology. 2010;4:508-514.
(2010)
Abstract
Guyton, JR. Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. Current Opinion in Lipidology. 2010;21:372-377.
(2010)
Abstract
Suchindran, S; Rivedal, D; Guyton, JR; Milledge, T; Gao, X; Benjamin, A; Rowell, J; Ginsburg, GS; McCarthy, JJ. Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genetics. 2010;6:e1000928.
(2010)
Abstract
Guyton, JR; Simmons, PD. Flushing and other dermatologic adverse events associated with extended-release niacin therapy. Journal of Clinical Lipidology. 2009;3:101-108.
(2009)
Abstract
Guyton, JR; Brown, BG; Fazio, S; Polis, A; Tomassini, JE; Tershakovec, AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology. 2008;51:1564-1572.
(2008)
Abstract
Guyton, JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Current Opinion in Lipidology. 2007;18:415-420.
(2007)
Abstract
